A sulfated disaccharide derived from chondroitin sulfate proteoglycan protects against inflammation‐associated neurodegeneration
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Chondroitin sulfate proteoglycan (CSPG), a matrix protein that occurs naturally in the central nervous system (CNS), is considered to be a major inhibitor of axonal regeneration and is known to participate in activation of the inflammatory response. The degradation of CSPG by a specific enzyme, chondroitinase ABC, promotes repair. We postulated that a disaccharidic degradation product of this glycoprotein (CSPG‐DS), generated following such degradation, participates in the modulation of the inflammatory responses and can, therefore, promote recovery in immune‐induced neuropathologies of the CNS, such as experimental autoimmune encephalomyelitis (EAE) and experimental autoimmune uveitis (EAU). In these pathologies, the dramatic increase in T cells infiltrating the CNS is far in excess of the numbers needed for regular maintenance. Here, we show that CSPG‐DS markedly alleviated the clinical symptoms of EAE and protected against the neuronal loss in EAU. The last effect was associated with a reduction in the numbers of infiltrating T cells and marked microglia activation. This is further supported by our in vitro results indicating that CSPG‐DS attenuated T cell motility and decreased secretion of the cytokines interferon‐? and tumor necrosis factor‐?. Mechanistically, these effects are associated with an increase in SOCS‐3 levels and a decrease in NF‐?B. Our results point to a potential therapeutic modality, in which a compound derived from an endogenous CNS‐resident molecule, known for its destructive role in CNS recovery, might be helpful in overcoming inflammation‐induced neurodegenerative conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammatory Blockade Restores Adult Hippocampal Neurogenesis
Monje, M. L., Toda, H., & Palmer, T. D. (2003) · Science · doi:10.1126/science.1088417 · Cited by 2,426
Chondroitinase ABC promotes functional recovery after spinal cord injury
Bradbury, E. J., Moon, L. D. F., Popat, R. J., King, V. R., Bennett, G. S., Patel, P. N., Fawcett, J. W., & McMahon, S. B. (2002) · Nature · doi:10.1038/416636a · Cited by 2,357 · cited 2×
“Therefore, accelerating its degradation has been proposed as a potential treatment approach for CNS injuries (11, 12, 15).”
BackgroundSchaefer, L., Babelova, A., Kiss, E., Hausser, H.-J., Baliova, M., Krzyzankova, M., Marsche, G., Young, M. F., Mihalik, D., Götte, M., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23755 · Cited by 850
Combs, C. K., Karlo, J. C., Kao, S.-C., & Landreth, G. E. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-04-01179.2001 · Cited by 721
Bjartmar, C., Wujek, J. R., & Trapp, B. D. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00069-2 · Cited by 573
McKeon, R. J., Jurynec, M. J., & Buck, C. R. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-24-10778.1999 · Cited by 480
Kotter, M. R., Setzu, A., Sim, F. J., Van Rooijen, N., & Franklin, R. J. M. (2001) · Glia · doi:10.1002/glia.1085 · Cited by 385
NF-κB as a therapeutic target in chronic inflammation: recent advances
Makarov, S. S. (2000) · Molecular Medicine Today · doi:10.1016/s1357-4310(00)01814-1 · Cited by 379
Efficient central nervous system remyelination requires T cells
Bieber, A. J., Kerr, S., & Rodriguez, M. (2003) · Annals of Neurology · doi:10.1002/ana.10578 · Cited by 196 · cited 1×
“Actually, the same myelin-directed T cells, which are destructive in EAE (where they are present in excessive levels), can promote recovery following spinal cord injury (69, 70) or induce remyelination (27), provided that their levels and the cytokines they produce are well controlled.”
BackgroundKitagawa, H., Tsutsumi, K., Tone, Y., & Sugahara, K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.50.31377 · Cited by 187 · cited 1×
“The 4-sulfated CSPG is most abundantly expressed in the developing CNS (60, 61).”
Background
Cited by
Traumatic Spinal Cord Injury: An Overview of Pathophysiology, Models and Acute Injury Mechanisms
Alizadeh, A., Dyck, S. M., & Karimi-Abdolrezaee, S. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00282 · Cited by 1,407
The bright side of the glial scar in CNS repair
Rolls, A., Shechter, R., & Schwartz, M. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2591 · Cited by 674
Self-citationRetinal microglia: Just bystander or target for therapy?
Karlstetter, M., Scholz, R., Rutar, M., Wong, W. T., Provis, J. M., & Langmann, T. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.11.004 · Cited by 551
Manipulating the glial scar: Chondroitinase ABC as a therapy for spinal cord injury
Bradbury, E. J., & Carter, L. M. (2011) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2010.06.015 · Cited by 314
Lee, H., McKeon, R. J., & Bellamkonda, R. V. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905437106 · Cited by 313
Metadata
- Authors
- Rolls, A., Cahalon, L., Bakalash, S., Avidan, H., Lider, O., & Schwartz, M.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2006-01-05
- Volume
- 20
- Issue
- 3
- Pages
- 547-549
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2136273681
- Cited by
- 89
- References
- 10
- FWCI
- 2.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A sulfated disaccharide derived from chondroitin sulfate proteoglycan protects against inflammation‐associated neurodegeneration. https://app.cochat.ai/papers/10.1096/fj.05-4540fje
- The paper
- Rolls, A., Cahalon, L., Bakalash, S., Avidan, H., Lider, O., & Schwartz, M. (2006). A sulfated disaccharide derived from chondroitin sulfate proteoglycan protects against inflammation‐associated neurodegeneration. The FASEB Journal. https://doi.org/10.1096/fj.05-4540fje
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.